Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Palliative Chemotherapy plus Controlled Diet with or without Metformin in Advanced Solid Tumors
KCT0005210Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2014
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Drugs
- metformin
- Conditions
- non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)advanced nonhematological malignancy
01
Overview
Phase 2, randomised trial of metformin in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and advanced nonhematological malignancy (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Feb 2014; status: completed.
02
Design
2 arms- Study design
- Randomized
Chemotherapy + controlled diet + metformin
Palliative chemotherapy plus controlled diet with adjunctive metformin.
Chemotherapy + controlled diet (no metformin)
Palliative chemotherapy plus controlled diet without metformin (active control).
03
Who it enrols
Adults with advanced solid tumors, including advanced non-small cell and small cell lung cancers, eligible for palliative chemotherapy; healthy volunteers excluded; typical performance status and safety exclusions assumed.
Beyond the preview
Go deeper on KCT0005210.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005210.